184 related articles for article (PubMed ID: 12826151)
21. The effect of extracorporeal photopheresis alone or in combination therapy on circulating CD4(+) Foxp3(+) CD25(-) T cells in patients with leukemic cutaneous T-cell lymphoma.
Shiue LH; Couturier J; Lewis DE; Wei C; Ni X; Duvic M
Photodermatol Photoimmunol Photomed; 2015 Jul; 31(4):184-94. PubMed ID: 25772268
[TBL] [Abstract][Full Text] [Related]
22. Photochemotherapy induces a faster apoptosis of alloreactive activated T cells than of nonalloreactive resting T cells in graft versus host disease.
Hannani D; Merlin E; Gabert F; Laurin D; Deméocq F; Chaperot L; Kanold J; Plumas J
Transplantation; 2010 Dec; 90(11):1232-8. PubMed ID: 21268310
[TBL] [Abstract][Full Text] [Related]
23. Successful implementation of a rural extracorporeal photopheresis program for the treatment of cutaneous T-cell lymphoma and chronic graft-versus-host disease in a rural hospital.
Weber LL; Dunbar NM; Meehan KR; Szczepiorkowski ZM; Lansigan F
J Clin Apher; 2015 Dec; 30(6):359-63. PubMed ID: 25691106
[TBL] [Abstract][Full Text] [Related]
24. Mini buffy coat photopheresis for children and critically ill patients with extracorporeal photopheresis contraindications.
Hackstein H; Misterek J; Nockher A; Reiter A; Bein G; Woessmann W
Transfusion; 2009 Nov; 49(11):2366-73. PubMed ID: 19903292
[TBL] [Abstract][Full Text] [Related]
25. Mechanisms of action of extracorporeal photochemotherapy.
Heshmati F
Transfus Apher Sci; 2003 Aug; 29(1):61-70. PubMed ID: 12877896
[TBL] [Abstract][Full Text] [Related]
26. Boost of innate immunity cytokines as biomarkers of response to extracorporeal photopheresis in patients with leukaemic cutaneous T-cell lymphoma.
Tsai YC; Schlaepfer T; Ignatova D; Chang YT; Valaperti A; Amarov B; Blanchard G; Pehr K; Vonow-Eisenring M; Urosevic-Maiwald M; Hoetzenecker W; Pascolo S; Iselin C; Fassnacht C; Dimitriou F; Bobrowicz M; Guenova E
Br J Dermatol; 2023 Oct; 189(5):603-611. PubMed ID: 37409661
[TBL] [Abstract][Full Text] [Related]
27. The North American experience with photopheresis.
Zic JA; Miller JL; Stricklin GP; King LE
Ther Apher; 1999 Feb; 3(1):50-62. PubMed ID: 10079806
[TBL] [Abstract][Full Text] [Related]
28. CD71 surface analysis of T cells: a simple alternative for extracorporeal photopheresis quality control.
Schwab L; Michel G; Bein G; Hackstein H
Vox Sang; 2020 Jan; 115(1):81-93. PubMed ID: 31680273
[TBL] [Abstract][Full Text] [Related]
29. Extracorporeal photopheresis: from solid organs to face transplantation.
Hivelin M; Siemionow M; Grimbert P; Lantieri L
Transpl Immunol; 2009 Jul; 21(3):117-28. PubMed ID: 19409991
[TBL] [Abstract][Full Text] [Related]
30. A simplified extracorporeal photopheresis procedure based on single high-dose ultraviolet A light irradiation shows similar in vitro efficacy.
Buchele V; Hackstein H
Transfusion; 2021 Mar; 61(3):883-893. PubMed ID: 33300629
[TBL] [Abstract][Full Text] [Related]
31. Extracorporeal photopheresis normalizes some lymphocyte subsets (including T regulatory cells) in chronic graft-versus-host-disease.
Bladon J; Taylor P
Ther Apher Dial; 2008 Aug; 12(4):311-8. PubMed ID: 18789119
[TBL] [Abstract][Full Text] [Related]
32. Extracorporeal photopheresis, a therapeutic option for cutaneous T-cell lymphoma and immunological diseases: state of the art.
Martino M; Fedele R; Cornelio G; Moscato T; Imbalzano L; Ressa G; Massara E; Bresolin G
Expert Opin Biol Ther; 2012 Aug; 12(8):1017-30. PubMed ID: 22587646
[TBL] [Abstract][Full Text] [Related]
33. Extracorporeal photopheresis for paediatric patients experiencing graft-versus-host disease (GVHD).
Rutella S; Valentini CG; Ceccarelli S; Romano MT; Brescia LP; Milano GM; Locatelli F
Transfus Apher Sci; 2014 Jun; 50(3):340-8. PubMed ID: 24780391
[TBL] [Abstract][Full Text] [Related]
34. In vitro PUVA treatment triggers calreticulin exposition and HMGB1 release by dying T lymphocytes in GVHD: New insights in extracorporeal photopheresis.
Coppard C; Hannani D; Humbert M; Gauthier V; Plumas J; Merlin E; Gabert F; Chaperot L
J Clin Apher; 2019 Aug; 34(4):450-460. PubMed ID: 30860623
[TBL] [Abstract][Full Text] [Related]
35. Modulation of lymphocyte subpopulations by extracorporeal photopheresis in patients with acute graft-versus-host disease or graft rejection.
Lorenz K; Rommel K; Mani J; Jin N; Hilgendorf I; Ho AD; Freund M; Schmitt M; Schmitt A
Leuk Lymphoma; 2015 Mar; 56(3):671-5. PubMed ID: 24913503
[TBL] [Abstract][Full Text] [Related]
36. Extracorporeal photochemotherapy.
Maeda A
J Dermatol Sci; 2009 Jun; 54(3):150-6. PubMed ID: 19369039
[TBL] [Abstract][Full Text] [Related]
37. Real-world use of extracorporeal photopheresis for patients with cutaneous T-cell lymphoma in the United States: 2010-2015.
Ling YL; Huang X; Mitri G; Lovelace B; Pham A; Knobler R; Li X; Gao X
J Dermatolog Treat; 2020 Feb; 31(1):91-98. PubMed ID: 30892982
[No Abstract] [Full Text] [Related]
38. Maturation state of dendritic cells during the extracorporeal photopheresis and its relevance for the treatment of chronic graft-versus-host disease.
Spisek R; Gasova Z; Bartunkova J
Transfusion; 2006 Jan; 46(1):55-65. PubMed ID: 16398731
[TBL] [Abstract][Full Text] [Related]
39. The role of extracorporeal photopheresis in the treatment of cutaneous T-cell lymphomas.
Atta M; Papanicolaou N; Tsirigotis P
Transfus Apher Sci; 2012 Apr; 46(2):195-202. PubMed ID: 22067605
[TBL] [Abstract][Full Text] [Related]
40. Mechanism of action of extracorporeal photochemotherapy in chronic graft-versus-host disease.
Fimiani M; Di Renzo M; Rubegni P
Br J Dermatol; 2004 Jun; 150(6):1055-60. PubMed ID: 15214889
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
